Second-line ASKB589 plus chemotherapy for advanced gastric or gastroesophageal cancers: Results from cohort 5 of a phase I/II study. Updated results of fruquintinib combined with PD-1 inhibitors and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback